Insulet announces FDA clearance of Omnipod GO

Insulet has announced the FDA clearance of Omnipod GO, an insulin delivery device cleared for use for people with tTpe 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.

Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. It features a tubeless and waterproof Pod and seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. It has been cleared for use with the following U-100 insulins: NovoLog, Fiasp, Humalog, Admelog, and Lyumjev.

The product was developed to serve people with Type 2 diabetes earlier in their treatment journey by starting them on Pod therapy for their insulin delivery, rather than daily injections. If a person becomes insulin-intensive, meaning they require both basal and bolus insulin, the transition to another Omnipod product would be seamless.

To read more, CLICK HERE.


Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags